TL;DR
Contin improvements in antibody engineering, linker optimization, payload development, computational modeling, and biomarker-guided patient selection are expected to further improve the therapeutic index and translational success of bsADCs in cancer treatment.
Bispecific antibodies (bsAbs) and bispecific antibody–drug conjugates (bsADCs) represent promising classes of emerging targeted therapeutics with the potential to overcome tumor heterogeneity and resistance in colorectal cancer (CRC). BsAbs can simultaneously engage multiple tumor antigens or immune cells or bind two d...
Peptide-drug conjugates (PDCs) are emerging as a next-generation class of targeted therapeutics designed to overcome key limitations associated with conventional chemotherapy and antibody-drug conjugates (ADCs). By integrating a tumor-homing peptide, a cleavable or stimuli-responsive linker, and a potent cytotoxic payl...
Preclinical investigation of trastuzumab-encapsulated actinomycin D, a HER2-targeted AED, has demonstrated potent antitumor activity across cancer models with varying HER2 expression levels, alongside a favorable toxicity profile in animal models, position AED as a promising next-generation targeted cancer therapy that...
BACKGROUND Bispecific antibody-drug conjugates (BsADCs) represent a promising therapeutic strategy to overcome single-target resistance. Here, we developed a dual-targeting BsADC that simultaneously recognizes CD44v6 and VEGFR2. METHODS Spatial configurations were optimized in CHO expression systems. In vitro binding...
Bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy in cancer immunotherapy, enabling simultaneous targeting of two distinct antigens to redirect immune effector cells, block compensatory pathways, and modulate the tumor immune microenvironment (TIME). Hundreds of BsAbs are currently in clini...
Continual advances in molecular engineering and precision biomarker strategies are redefining ADCs as versatile platforms for precision oncology and may enable broader, potentially tumor-agnostic, applications in solid tumors.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
